ArticleScientific reports2025
Gene signatures and genotype-phenotype correlations of sensorineural hearing loss in Noonan syndrome and related RASopathies.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical and Molecular Portraits of Pediatric RASopathies: A Study of 118 Genotype-Confirmed Cases.Clinical genetics · 2026Article
- Clinical phenotypes and cochlear implant outcomes in patients with PTPN11-associated noonan spectrum disorders: Insights from a genetically screened cohort.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Molecular Diagnosis and Phenotypic Variability of Noonan Syndrome: Experience from a Romanian Multicenter Study.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hearing loss frequently occurs in Noonan syndrome and related RASopathies (NS-RAS), with conductive hearing loss being common. However, the genotypic and phenotypic features of sensorineural hearing loss (SNHL) in NS-RAS, as well as genotype-phenotype correlations, remain unknown. Leveraging in-house database for syndromic deafness (N = 1666), we analyzed the genomic landscape and clinical phenotypes of 94 NS-RAS families with genetically confirmed via targeted panel sequencing. In particular, we explored the genetic signature of SNHL in NS-RAS and provided a detailed description of the auditory characteristics of SNHL, including its natural progression and outcomes of audiological rehabilitation. Additionally, molecular modeling and functional assays were conducted to explore how PTPN11 variants with distinct auditory phenotypes affect downstream signaling pathways. Resultantly, eighteen (19.1%) exhibited SNHL, predominantly with PTPN11 (88.9%) and RAF1 (11.1%) variants. Of these patients, the majority exhibited severe-to-profound SNHL with congenital onset, and cochlear implantation yielded favorable auditory outcomes. The remaining patients maintained normal hearing throughout the follow-up periods. The PTPN11 variants linked to SNHL compromise autoinhibition between the N-SH2 and PTP domains or disrupts the interaction between the C-SH2 domain and phosphorylated tyrosine (pTyr), showing a gain-of-function effect on the RAS/ERK cascade. Specifically, those variants associated with high penetrance and severe expressivity significantly enhanced ERK phosphorylation more than the variants associated with low penetrance and milder expressivity. This is the first cohort study on NS-RAS in South Korea, elucidating the gene signatures and phenotypic characteristics of SNHL and suggesting genotype-auditory phenotype correlations that inform clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.